Hyderabad is emerging as a life sciences hub, with global and domestic pharmaceutical firms expanding or setting up facilities in the city, including Eurofin, Syngene, and Piramal, say industry experts.

The city has secured over $700 million in investments within the past year and is projected to reach $250 billion by 2030.

“The Government of Telangana is committed to providing an inspiring ecosystem for the growth of the life sciences industry as illustrated by the ambitious target for the life sciences ecosystem in the region to reach $ 250 billion by 2030. To achieve this, we are actively working towards creating world-class infrastructure, promoting research and development, and providing a skilled workforce to accelerate innovation,” said Telangana IT and Industries Minister K T Rama Rao.

Hyderabad is the only city in India expanding its life science park—Genome Valley, Medtech Park, and the upcoming world’s largest, Pharma City.

Currently, 4 of the top 10 global innovator companies—Novartis, BMS, Sanofi, and Roche—have a direct presence in Hyderabad through their dedicated centres.

Yapan Bio has grown significantly since its establishment in Genome Valley, Hyderabad, in 2019.

“Genome Valley provides an opportunity for young companies to establish and grow while staying asset-light so that the capital can be utilised for core R&D activities rather than infrastructure setup. As a services-focused startup, being a part of this cluster helps access ready infrastructure, potential partners, and scientific talent, which are critical for the success and growth of any organisation,” said Atin Tomar, founder and CEO of Yapan Biotech. Mahesh Bhalgat, COO of Syngene, said, “This location has evolved into a thriving life sciences ecosystem, which is ideal for fast-growing organisations like Syngene to connect with potential partners, collaborators, and talent. Syngene’s first operational research centre outside Bangalore commenced in Genome Valley in 2019. Over the last three years, the employee base has grown to almost 1000.”

Rx Propellant has invested Rs 1,100 crore in a lab space development project at Genome Valley in Hyderabad, utilising the $200 million infusion from global fund Actis for life sciences real estate development. The company is also engaged in developing and marketing multiple real estate projects in the design-development stages in Hyderabad and Bangalore, aimed at the life sciences sector.

“India is a major global player in life sciences and will have approximately 10 percent of its office inventory dedicated to life sciences, which translates to 100 million square feet of opportunity by 2030. Genome Valley will retain its advantage as other clusters catch up and cater to 40 percent of national demand,” said Vishal Goel, MD, RX Propellant.

Hyderabad, is a hub for the pharmaceutical, vaccine, and biotechnology sectors, hosting top players at the forefront of innovation and attracting investments of more than $3 billion from companies such as Novartis, BMS, Sanofi, and Roche, which have generated over 450,000 jobs in the last seven years.

Telangana IT and Industries Minister K.T. Rama Rao aims to position the city as the “Health-Tech Mecca” of the world.

The increasing government spending on healthcare and cost benefits such as affordable human resources, lower real estate expenses compared to other global markets, and growing biotech startups are seen as critical catalysts of growth for India’s life science sector, according to industry experts.